A good analytical result is valuable because it answers a defined question. Its value is weakened, not strengthened, when it is presented as proof of everything else. For a no-DAC CJC preparation, identifying an expected molecule does not by itself establish clinical suitability.
A GHRH analytical-method study developed specialist detection using immunoaffinity purification and high-resolution mass spectrometry. The work evaluated method performance for specified analytes and samples. It was not a clinical trial proving that a detected peptide is safe to administer.
A later study of seized material found analogues of several secretagogues, including modified GRF 1-29, carrying an extra glycine at the amino terminus. Comparison with reference standards established these modified identities. The finding does not show how common substitution is across suppliers; the samples were a selected forensic set. It does show why a familiar name cannot exclude a chemically different analogue. Primary seizure study, PMID 30136411
What exactly was validated?
A method can be validated for identity, detection or quantification under particular conditions. Those are not interchangeable purposes. The sample matrix, reference materials and potential interferences influence what a reported result can support.
A positive identity result also does not automatically characterize every impurity. Nor does it establish microbiological quality. Those questions need appropriate methods of their own. The presence of the expected molecule and the absence of all unacceptable hazards are different propositions.
Clinical claims are a further step. Even a thoroughly characterized preparation may have insufficient evidence for the proposed route, population or benefit. Analytical certainty about composition cannot substitute for a controlled study of outcomes.
This distinction is useful when a certificate is used in place of a research citation. A certificate may support a batch-specific attribute; a clinical paper may support an outcome for a tested intervention. Neither should be made to do the other's job.
The reader's task is to ask what the result actually measures and what remains outside its scope. That is more informative than treating “mass spectrometry tested” as a general safety badge. An analytical match does not approve a no-DAC CJC product for human use or prove a therapeutic effect; the limits of each test still matter.